Fiche société
Ipsen
Traitements, essais et publications liés.
Traitements18programmes
Essais12liés
Publications21liées
SourceDBlocale
Traitements
18| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine, Myopathies | Phase 2 | Traitement symptomatique | Czechia, Poland, Slovakia | À vérifier |
| CorabotaseA migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of Corabotase to inject at each point, * The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks. | Migraine | Phase 2 | Traitement symptomatique | United States, Australia, Brazil, Canada, Czechia, France, Georgia, Germany, … | À vérifier |
| Corabotase dose AA migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of Corabotase to inject at each point, * The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks. | Migraine | Phase 2 | Traitement symptomatique | United States, Australia, Brazil, Canada, Czechia, France, Georgia, Germany, … | À vérifier |
| Corabotase dose BA migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of Corabotase to inject at each point, * The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks. | Migraine | Phase 2 | Traitement symptomatique | United States, Australia, Brazil, Canada, Czechia, France, Georgia, Germany, … | À vérifier |
| EGb 761® (Tanakan®)The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type. | Alzheimer | Phase 4 | Ralentissement de la progression | France | À vérifier |
| FOPal — A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)). HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups). This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene. The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene. This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance. In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene. | Myopathies | À vérifier | Traitement symptomatique | United States, Canada | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Myopathies | Phase 2 | Traitement symptomatique | Czechia, Germany, Italy, Poland, Portugal, Spain | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine | Phase 3 | Traitement symptomatique | United States, Canada, Czechia, Georgia, Germany, Italy, Poland, Spain, United Kingdom | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine | Phase 3 | Traitement symptomatique | United States, Canada, Czechia, France, Georgia, Germany, Poland, Spain | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine | Phase 4 | Traitement symptomatique | Netherlands | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine | Phase 2 | Traitement symptomatique | Czechia, Poland, Slovakia | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine | Phase 4 | Traitement symptomatique | South Korea | À vérifier |
| EGb 761® (Tanakan®)The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type. | Alzheimer | Phase 4 | Ralentissement de la progression | France | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Migraine | Phase 3 | Traitement symptomatique | Norway | À vérifier |
| CorabotaseA migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. Corabotase (also known as IPN10200) is a medication that stops the release of these chemical messengers. Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. "Headache days" are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. "Migraine days" occur when the headache displays clear migraine characteristics. This study aims to determine: * The safety and efficacy of injecting Corabotase directly into the muscles of the head and neck to prevent EM and CM, * The right amount (dose) of Corabotase to inject at each point, * The total amount (dose) of Corabotase that provides the best balance between safety and efficacy preventing migraines. Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 44 weeks. | Migraine | Phase 2 | Traitement symptomatique | United States, Australia, Brazil, Canada, Czechia, France, Georgia, Germany, Japan, New Zealand, Poland, South Korea, Spain, United Kingdom | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Myopathies | Non applicable | Traitement symptomatique | Spain | À vérifier |
| Botulinum toxin type AThe main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain. The study will also examine the side effects of this treatment and its overall effect on one's disorder. | Myopathies | Phase 2 | Traitement symptomatique | Sweden | À vérifier |
| FOPal — A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)). HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups). This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene. The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene. This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance. In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene. | Myopathies | À vérifier | Traitement symptomatique | United States, Canada | À vérifier |
Essais cliniques
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| FOPal — A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | Myopathies | À vérifier | NCT06089616 | FOPal — A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP) | RECRUITING |
| Botulinum toxin type A | Myopathies | Phase 2 | NCT05720065 | Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A | RECRUITING |
| Botulinum toxin type A | Myopathies | Non applicable | NCT07758322 | Efficacy of Focused Shock Wave Therapy Before and After Botulinum Toxin Injection in Patients With Post-Stroke Spastic Equinus/Equinovarus Foot: A Randomized Clinical Trial | ACTIVE_NOT_RECRUITING |
| Corabotase | Migraine | Phase 2 | NCT06625060 | MERANTI — A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT04069897 | MiBlock — Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine | COMPLETED |
| EGb 761® (Tanakan®) | Alzheimer | Phase 4 | NCT00276510 | A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints | COMPLETED |
| Botulinum toxin type A | Migraine | Phase 4 | NCT02147561 | A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine | COMPLETED |
| Botulinum toxin type A | Migraine | Phase 2 | NCT00301665 | Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis | COMPLETED |
| Botulinum toxin type A | Migraine | Phase 4 | NCT06448676 | Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides | RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047457 | E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047444 | C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Myopathies | Phase 2 | NCT00134810 | Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome | COMPLETED |
Publications
21| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Corabotase dose A | Healthcare use and out-of-pocket costs for rural family caregivers and care recipients in a randomized controlled trial. | Journal of the American Geriatrics Society | ||
| Corabotase dose A | Transitional Palliative Care for Family Caregivers: Outcomes From a Randomized Controlled Trial. | Journal of pain and symptom management | ||
| Corabotase dose A | Caregiver Communication and Preparedness During Transitions in Care: Results from a Randomized Controlled Trial. | Journal of palliative medicine | ||
| Botulinum toxin type A | Catamenial loss of botulinum toxin efficacy successfully managed with tamoxifen: A case report. | JAAD case reports | ||
| Botulinum toxin type A | Early local antitoxin intervention attenuates botulinum neurotoxin-induced neuromuscular dysfunction. | Toxicon : official journal of the International Society on Toxinology | ||
| Botulinum toxin type A | Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids. | The Journal of dermatological treatment | ||
| Botulinum toxin type A | Short-term quantitative ultrasonographic assessment of masseter muscle changes following botulinum toxin injection in patients with bruxism: A prospective pilot study. | Cranio : the journal of craniomandibular practice | ||
| Botulinum toxin type A | The STIIM UP Protocol: Exploratory Evaluation of the Potential of Combined Calcium Hydroxyapatite, Hyaluronic Acid, and Botulinum Toxin A in Neck Rejuvenation. | Journal of clinical medicine | ||
| Botulinum toxin type A | [Treatment persistence and adherence with botulinum toxin type A and anti-calcitonin gene-related peptide monoclonal antibodies in migraine. (A retrospective cohort study from a specialized headache center)]. | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova | ||
| Botulinum toxin type A | Diagnostic value of shear wave elastography in assessing the effectiveness of preoperative botulinum toxin type A therapy in patients with postoperative ventral hernias W3. | Hernia : the journal of hernias and abdominal wall surgery | ||
| EGb 761® (Tanakan®) | Dementia as a rare neurological adverse event of Nivolumab in a patient with metastatic renal cell carcinoma. | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | ||
| EGb 761® (Tanakan®) | Adjunctive EGb 761 treatment in patients with Parkinson's disease: a case series. | Frontiers in aging neuroscience | ||
| Botulinum toxin type A | Botulinum Toxin Type A for the Treatment of Focal Spasticity in Children With Cerebral Palsy in Thailand: A Cost-Utility and Budget Impact Analysis. | Value in health regional issues | ||
| Botulinum toxin type A | Comparing the real-world effectiveness of botulinum toxin type A injections across distinct poststroke muscle hyper-resistance patterns. | Frontiers in neurology | ||
| Botulinum toxin type A | Therapeutic progress in rosacea: targeting the neuro-vascular-immune triad. | Frontiers in immunology | ||
| Botulinum toxin type A | Advanced on Minimally Invasive Techniques in Facial Rejuvenation: A Comprehensive Review. | World journal of plastic surgery | ||
| Botulinum toxin type A | The Efficacy of Laser and Botox Therapies for Post-Thyroidectomy Scar Management: A Comprehensive Systematic Review and Meta-Analysis. | Aesthetic plastic surgery | ||
| Botulinum toxin type A | Association of AbobotulinumtoxinA and Skinbooster for Periorbital Wrinkles: A Randomized, Controlled, Double-Blind, Split-Face Study. | Aesthetic plastic surgery | ||
| Botulinum toxin type A | One-day rejuvenation: a preliminary case series of a multimodal protocol combining Q-switched 1064 nm laser, botulinum toxin, and laser-assisted delivery of PDRN and retinoids. | Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology | ||
| Botulinum toxin type A | Long-term neuromuscular alterations during botulinum toxin treatment for chronic migraine. | Clinical neurophysiology practice | ||
| Botulinum toxin type A | Geographic Variation in Botulinum Toxin Type A Longevity: A Pilot Comparative Study Between Saint Petersburg and Ashgabat. | Cureus |